About this trial
A qualitative interview study exploring the patient and provider perspectives on the clinical utility of genetic risk profiling in routine clinical practice. The findings from the study may contribute towards future research and informing clinical practice.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Individuals assigned male at birth who are aged 18 and over and who have capacity to consent
Patients who have undergone genetic risk profiling for prostate cancer and have received their results
Individuals from diverse backgrounds (age, ethnicity, risk status, etc)
Healthcare providers who have delivered a genetic risk profiling result for prostate cancer
Disqualifiers
Individuals who lack capacity to consent
Individuals deemed unsuitable to recruit based on their poor performance status or current medical condition
Trial population
Patients who have undergone and received a genetic risk profiling result for prostate cancer and healthcare providers who have delivered a genetic risk profiling result for prostate cancer
Trial design
Cohort
Prospective
Treatments tested in this trial
Qualitative interview
Other interventionInterview of participants to gain perspectives and experiences
Treatment groups
Trial outcomes
Primary outcomes
Data pertaining to the experiences and perspectives of healthcare providers and patients regarding the clinical utility of genetic risk profiling in routine clinical practice, using a qualitative (interview) thematic analysis approach.
The study findings will provide data pertaining to the current experiences, perspectives, benefits, limitations and challenges patients and providers encounter when receiving and delivering genetic risk profiling results. The findings can help to highlight areas of concern which need to be addressed, improved and/or implemented prior to clinical implementation of genetic risk profiling into routine clinical care. The findings can also identify the educational, clinical and/or support needs and may also highlight aspects of clinical care which need to be improved or established (e.g. screening guidelines, resources, upskilled workforce) prior to the integration of genetic risk profiling into routine clinical practice. This will ensure that genetic risk profiling is relevant and feasible in terms of improving the clinical care and health seeking behaviours of patients.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Royal Marsden NHS Foundation Trust
Lead sponsor
Institute of Cancer Research, United Kingdom
Collaborator